Geschäftsleitung
Aufsichtsrat
Investoren
Geschichte
Geschäftsstrategie
Pressemitteilungen und Nachrichten
FAQs
Home
Über uns
Geschäftsleitung
Aufsichtsrat
Investoren
Geschichte
Geschäftsstrategie
Pressemitteilungen und Nachrichten
FAQs
Wissenschaft und Technologie
Gebärmutterhalskrebs-
Screening
p16
INK4a
CINtec® p16
INK4a
Färbeatlas
Links
Literatur/Unterlagen
Häufig gestellte Fragen
Produkte
CINtec® Histology
CINtec® Cytology
Cervatec™
Bestellung von Produkten
CINtec® p16
INK4a
Färbeatlas
Literatur/Unterlagen
Häufig gestellte Fragen
Ansprechpartner
Anfahrt zu den Büros
Karriere
Händler
Pressemitteilungen und Nachrichten
17.11.2008
mtm's CINtec Cytology Kit has higher specificity than HR-HPV testing improving the detection of cervical disease
13.11.2008
mtm laboratories AG to present at BIO-Europe 2008 in Mannheim/Heidelberg
17.09.2008
mtm laboratories launches CINtec
?
Cytology kit in Europe with extended clinical claims for cervical cancer diagnosis
01.07.2008
mtm laboratories appoints Bob Silverman as CEO
03.06.2008
Eine gelungene Veranstaltung! Das CINtec® Advanced Training vom 26. bis 27. April 2008 in Frankfurt
17.04.2008
mtm laboratories today announced the signing for a third tranche of Euro 9.6 million to its Series C funding. This addition increases the total for the round to Euro 31.6 million (USD 50 million) in equity
05.02.2008
mtm laboratories launches Cervatec® Assay for cervical cancer screening - New test significantly more sensitive in screening for cervical cancer than Pap Test
06.11.2007
The Clinical Utility of p16 as a Biomarker in Cervical Cancer Screening - Highlights from a satellite symposium held at EUROGIN 2007
01.11.2007
Hot pick of the month: mtm's p16 biomarker takes subjectivity out of cervical cancer screening
11.07.2007
mtm laboratories announces new pivotal trial data resulting in European launch of the CINtec® Histology kit with extended clinical claims
15.05.2007
Studies present compelling data on the p16
INK4a
biomarker at the 16th International Congress of Cytology
04.01.2007
mtm laboratories opens subsidiaries in Italy, France and Spain to support the commercialization of its diagnostic products.
03.01.2007
mtm laboratories launches proprietary CINtec® Histology and CINtec® Cytology kits.
09.10.2006
mtm laboratories raises €22 million in Series C financing.
11.07.2006
mtm laboratories makes two senior clinical research appointments.
04.05.2006
Studies presented at EUROGIN highlight potential of p16
INK4a
as biomarker for early detection and diagnosis of cervical cancer.
02.05.2006
mtm laboratories and Dako restructure license agreement regarding p16
INK4a
CINtec®.
02.08.2005
mtm laboratories AG establishes US subsidiary, naming Robert Silverman President.
13.10.2004
mtm laboratories achieves ISO 9001 and ISO 13485 certification for design, manufacturing and distribution of In Vitro Diagnostics.
03.05.2004
mtm laboratories announces granting of US patent covering its CINtec™ technology.
22.03.2004
mtm laboratories extends its supervisory board.
16.12.2003
Contribution to assessment of cervical cancer.
Language
français
italiano
español
english
Products
Find more about mtm's CINtec® product family
more
News
Die aktuellste Pressemitteilung der mtm AG vom 17. November 2008 lesen Sie hier:
mehr